Ligand id: 1015

Name: fulvestrant

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 15
Topological polar surface area 76.74
Molecular weight 606.32
XLogP 10.61
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Fulvestrant is used to treat hormone receptor-positive (HR +ve) metastatic breast cancer in post-menopausal women. In Septenber 2017, fulvestrant was FDA approved as a first-line monotherapy for HR +ve, HER2 -ve advanced breast cancer in endocrine-therapy näive, post-menopausal women.
Mechanism Of Action and Pharmacodynamic Effects
Fulvestrant binds to estrogen receptors present in cancer cells and leads to receptor desensitisation and degradation, such that estrogen-responsiveness is lost and the cancer cells die.